secwatch.observer — SEC 8-K summary
======================================

Issuer:     ProMIS Neurosciences Inc. (PMN)
CIK:        0001374339
Form:       8-K
Filed at:   2025-08-13T23:59:59+00:00
Accession:  0001558370-25-011297
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ProMIS Neurosciences Q2 net loss $10.1M; PRECISE-AD enrollment >50%, no ARIA; raised $21.6M in July
--------------------------------------------------------------------------------

- Net loss $10.1M for Q2 2025 vs $2.6M a year ago; R&D spend $8.7M on PRECISE-AD trial.
- Cash $4.5M at June 30; raised $21.6M gross proceeds in July via offerings and warrant exercises.
- PRECISE-AD Phase 1b: over 50% of 128 patients enrolled; no ARIA or dropouts to date.
- FDA granted Fast Track Designation for PMN310 in Alzheimer's disease in July 2025.
- Company expects blinded interim results in 2Q 2026, final topline in 4Q 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1374339/000155837025011297/0001558370-25-011297-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1374339/000155837025011297/pmn-20250813x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-011297

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer